Biotech ETFs offer diversified exposure to multiple biotech stocks, reducing individual investment risk. Top biotech ETFs, like iShares and SPDR S&P, have large assets and low expense ratios.

Despite its sharp rebound, the sector remains about 40% below its pandemic peak, leaving it as one of the few areas of the ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31 ...

The iShares Biotechnology ETF (IBB) provides exposure to healthcare innovation with a focus on the biggest firms by market ...

IBB offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller ...

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

The SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. Products that are ...

Biotech is outperforming the S&P 500 and NASDAQ as M&A heats up and Q4 tailwinds emerge, signaling more upside ahead. Read ...